Illumina Wins Legal Battle Against EU Over Grail Acquisition
Illumina, a U.S. gene sequencing company, won a key legal battle against the European Union this week regarding its $7.1 billion acquisition of cancer diagnostic test maker Grail.
Illumina, a U.S. gene sequencing company, won a key legal battle against the European Union this week regarding its $7.1 billion acquisition of cancer diagnostic test maker Grail.